Skip to main content

Pelvic Nodal clinical trials at UCSF
1 in progress, 1 open to new patients

  • Trial of Radiotherapy With Leuprolide and Enzalutamide in High Risk Prostate

    open to eligible males ages 18 years and up

    This is a phase II study to evaluate efficacy, safety, toxicity, and feasibility of the addition of enzalutamide to leuprolide for a total duration of 24 months in patients with very high-risk prostate cancer or pelvic node positive disease receiving radiotherapy. Very high-risk prostate cancer is defined as 2 or more of the following characteristics: 1) cT3a/b, 2) PSA ≥20 and <150, 3) Gleason 8-10, and 4) ≥33% core involvement.

    San Francisco, California